Advent Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Advent Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-36,900	Closed	-$2.35M	–	249
2025 Q1	$2.35M	Buy	+36,900	New	+$3.88M	0.05%	165
2024 Q3	–	Sell	-10,000	Closed	-$1.38M	–	244
2024 Q2	$1.58M	Sell	10,000 -10,000	-50%	-$1.28M	0.04%	148
2024 Q1	$2.59M	Buy	20,000 +6,000	+43%	+$735K	0.07%	128
2023 Q4	$1.35M	Buy	+14,000	New	+$1.34M	0.03%	163
2023 Q2	–	Sell	-560	Closed	-$77.2K	–	247
2023 Q1	$77.2K	Buy	+560	New	+$72.6K	﹤0.01%	203
2019 Q2	–	Sell	-2,000	Closed	-$238K	–	225
2019 Q1	$238K	Buy	+2,000	New	+$257K	0.01%	180

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Advent Capital Management's SRPT Position: Q2 2025 in Review

Advent Capital Management sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 36,900 shares — an estimated $2.35M sold.

Advent Capital Management first reported a position in SRPT in Q1 2019 and held it in 6 quarters. The position peaked at $2.59M in Q1 2024. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

Advent Capital Management reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
Advent Capital Management sold 36,900 Sarepta Therapeutics shares in Q2 2025, an estimated $2.35M.
Advent Capital Management first reported a position in Sarepta Therapeutics in Q1 2019 and held it in 6 quarters.
Advent Capital Management's Sarepta Therapeutics position peaked at $2.59M in Q1 2024.
362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Advent Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.